Table 2 Correlation of TASL expression with clinicopathological parameters in 71 patients with glioma
Characteristics | TASL expression | P | |
|---|---|---|---|
Low (%) | High (%) | ||
Age (years) | |||
< = 45 | 16 (22.5) | 4 (5.6) | 0.003 |
> 45 | 19 (26.8) | 32 (45.1) | |
Gender | |||
Male | 22 (31) | 19 (26.8) | 0.536 |
Female | 13 (18.3) | 17 (23.9) | |
WHO grade | |||
G1 | 1 (1.5) | 0 (0) | < 0.001a |
G2 | 14 (21.5) | 0 (0) | |
G3 | 9 (13.8) | 8 (12.3) | |
G4 | 8 (12.3) | 25 (38.5) | |
Histological type | |||
Oligodendrogliomas | 4 (6.5) | 2 (3.2) | 0.001a |
Oligoastrocytomas | 5 (8.1) | 2 (3.2) | |
Astrocytoma | 12 (19.4) | 4 (6.5) | |
Glioblastoma multiforme | 8 (12.9) | 25 (40.3) | |
IDH1 status | |||
WT | 10 (27.8) | 17 (47.2) | 0.018a |
Mut | 8 (22.2) | 1 (2.8) | |
OLIG2 | |||
Negative | 1 (1.7) | 4 (6.8) | 0.353a |
Positive | 28 (47.5) | 26 (44.1) | |
Ki-67 positive (%) | |||
< 50 | 26 (40) | 21 (32.3) | 0.190 |
> = 50 | 6 (9.2) | 12 (18.5) | |